{"id":"adjuvant-chemotherapy-for-experimental-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant chemotherapy is a treatment strategy rather than a single drug, involving the use of chemotherapeutic agents (such as alkylating agents, platinum compounds, or antimetabolites) given following surgery or primary therapy. The goal is to target micrometastatic disease and improve overall survival by reducing the likelihood of cancer recurrence. The specific mechanism depends on the chemotherapy regimen selected for the experimental group.","oneSentence":"Adjuvant chemotherapy uses cytotoxic drugs administered after primary treatment to eliminate residual cancer cells and reduce recurrence risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:12.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment in experimental oncology trial (specific cancer type not specified)"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT07044453","phase":"PHASE2, PHASE3","title":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-12-08","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":390},{"nctId":"NCT07400302","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2026-02-01","conditions":"Mucosal Melanoma, PD-L1 Positive","enrollment":220},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT07379255","phase":"","title":"Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-01-01","conditions":"Bladder Cancer","enrollment":266},{"nctId":"NCT07369882","phase":"NA","title":"Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-12","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT04959500","phase":"PHASE2","title":"Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-07-21","conditions":"Glioblastoma","enrollment":150},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06088381","phase":"PHASE2","title":"Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2024-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer","enrollment":61},{"nctId":"NCT07204132","phase":"NA","title":"Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-09-01","conditions":"Bladder Cancer","enrollment":180},{"nctId":"NCT05116072","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-02-20","conditions":"Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma","enrollment":36},{"nctId":"NCT07010939","phase":"","title":"A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients","status":"RECRUITING","sponsor":"FangYi","startDate":"2025-04-07","conditions":"Breast Neoplasms, Quality of Life (QOL), Toxicities","enrollment":3000},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT04555226","phase":"NA","title":"The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2021-01-11","conditions":"Cervical Cancer","enrollment":452},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT06427252","phase":"PHASE2","title":"The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-31","conditions":"Gastric Cancer, Metastatic","enrollment":50},{"nctId":"NCT07038460","phase":"PHASE2","title":"A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Wen-zhao ZHONG","startDate":"2025-07","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":134},{"nctId":"NCT04174079","phase":"NA","title":"Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-12-11","conditions":"Thoracic Esophageal Squamous Cell Carcinoma","enrollment":232},{"nctId":"NCT06190249","phase":"PHASE1","title":"Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma","status":"WITHDRAWN","sponsor":"James Isaacs, MD","startDate":"2024-12-02","conditions":"Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma","enrollment":""},{"nctId":"NCT06977893","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-24","conditions":"HR+/HER2- Breast Cancer","enrollment":194},{"nctId":"NCT06920810","phase":"PHASE4","title":"Viscum Album for TNBC on Adjuvant Pembrolizumab","status":"RECRUITING","sponsor":"Ilsan Cha hospital","startDate":"2025-03-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":40},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT05063136","phase":"PHASE3","title":"Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-09-28","conditions":"Breast Cancer","enrollment":1979},{"nctId":"NCT05496491","phase":"NA","title":"Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Larissa University Hospital","startDate":"2022-08-30","conditions":"Rectal Neoplasms","enrollment":84},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT06597227","phase":"PHASE4","title":"Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Guihua Wang","startDate":"2024-03-01","conditions":"Locally Advanced Gastric Cancer","enrollment":404},{"nctId":"NCT05239663","phase":"PHASE3","title":"GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-02-08","conditions":"Chemotherapy-Related Cognitive Impairment, Breast Cancer","enrollment":76},{"nctId":"NCT06434376","phase":"EARLY_PHASE1","title":"MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2024-07-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT06435559","phase":"NA","title":"CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer: Impact of Cognitive Rehabilitation (CHEMOFOG)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2024-06-01","conditions":"Breast Cancer","enrollment":128},{"nctId":"NCT03714490","phase":"PHASE2","title":"MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2018-10-23","conditions":"Rectal Neoplasms","enrollment":200},{"nctId":"NCT05911217","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"CARsgen Therapeutics Co., Ltd.","startDate":"2023-07-11","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06403943","phase":"PHASE4","title":"Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-05-29","conditions":"Adjuvant, Treatment, Tuberculosis","enrollment":292},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT06357598","phase":"PHASE4","title":"Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-01-18","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT05890742","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-05-25","conditions":"MSI-H","enrollment":360},{"nctId":"NCT05913895","phase":"NA","title":"The Effect of Hydrogen Water in Oral Mucositis in Head and Neck Cancer Patients After Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2023-12-24","conditions":"Head and Neck Cancer, Oral Mucositis, Pain","enrollment":30},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT05966441","phase":"PHASE2","title":"Role of Curcumin in Paclitaxel Induced PN","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-08-30","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":80},{"nctId":"NCT05157776","phase":"PHASE3","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","status":"UNKNOWN","sponsor":"Tongji University","startDate":"2021-10-28","conditions":"NSCLC, Stage IIIA, EGF-R Negative Non-Small Cell Lung Cancer, ALK Negative NSCLC","enrollment":72},{"nctId":"NCT03038256","phase":"PHASE2","title":"Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-01-31","conditions":"Rectal Cancer, Pathological Complete Response, Disease Free Survival","enrollment":244},{"nctId":"NCT01558921","phase":"PHASE3","title":"Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2011-06-21","conditions":"Rectal Cancer","enrollment":920},{"nctId":"NCT05680662","phase":"EARLY_PHASE1","title":"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2023-01-01","conditions":"Breast Cancer Female, Triple Negative Breast Cancer","enrollment":200},{"nctId":"NCT04744649","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-03-12","conditions":"Gastric Cancer, Stomach Neoplasm","enrollment":110},{"nctId":"NCT04848454","phase":"PHASE2","title":"Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2021-11-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response","enrollment":30},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT05374252","phase":"PHASE3","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-05-07","conditions":"Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer","enrollment":102},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT04889820","phase":"NA","title":"Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Catholic University of Korea","startDate":"2021-11-01","conditions":"Colon Cancer, Obstruction","enrollment":204},{"nctId":"NCT04664504","phase":"PHASE2","title":"A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk","status":"UNKNOWN","sponsor":"Jing Jin, M.D.","startDate":"2020-12-01","conditions":"Rectal Cancer","enrollment":150},{"nctId":"NCT04899713","phase":"","title":"NEOZOL_Follow-up Study","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2021-05","conditions":"Locally Advanced Breast Cancer","enrollment":50},{"nctId":"NCT04762030","phase":"PHASE2","title":"Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT04351867","phase":"PHASE3","title":"A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer","status":"UNKNOWN","sponsor":"LiNing","startDate":"2020-09","conditions":"Stomach Neoplasms","enrollment":196},{"nctId":"NCT04261920","phase":"PHASE4","title":"Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction","status":"UNKNOWN","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2020-01-03","conditions":"Oncology","enrollment":360},{"nctId":"NCT04255771","phase":"PHASE3","title":"A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion","status":"UNKNOWN","sponsor":"Qinghua Xia,Prof","startDate":"2020-03-01","conditions":"Chemotherapy Effect","enrollment":200},{"nctId":"NCT03693248","phase":"PHASE3","title":"Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-12-19","conditions":"Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV, Fallopian Tube Cancer","enrollment":298},{"nctId":"NCT03373058","phase":"PHASE3","title":"Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2019-10-15","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":310},{"nctId":"NCT03961373","phase":"PHASE3","title":"Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer","status":"RECRUITING","sponsor":"University of Siena","startDate":"2018-11-05","conditions":"Locally Advanced Gastric Cancer","enrollment":539},{"nctId":"NCT03671252","phase":"PHASE3","title":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-11-16","conditions":"Rectal Cancer","enrollment":776},{"nctId":"NCT03468712","phase":"NA","title":"Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2018-03-31","conditions":"Complications, Postoperative, Surgery--Complications, Cancer of Stomach","enrollment":166},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT03601988","phase":"PHASE3","title":"Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2018-07-28","conditions":"Gastric Cancer","enrollment":408},{"nctId":"NCT03561740","phase":"PHASE3","title":"A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-07-25","conditions":"Breast Cancer","enrollment":794},{"nctId":"NCT03574324","phase":"PHASE3","title":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-05-24","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03177382","phase":"PHASE3","title":"Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2017-06-15","conditions":"Total Neoadjuvant Treatment, Chemoradiotherapy, Local Advanced Rectal Cancer","enrollment":458},{"nctId":"NCT03180177","phase":"PHASE3","title":"Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Shu-Zhong Cui","startDate":"2018-03-01","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":263},{"nctId":"NCT01216527","phase":"PHASE3","title":"Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-06","conditions":"Squamous Cell Esophageal Carcinoma","enrollment":430},{"nctId":"NCT01996410","phase":"NA","title":"The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients","status":"TERMINATED","sponsor":"OhioHealth","startDate":"2013-11","conditions":"Breast Cancer Stages I Through III","enrollment":10},{"nctId":"NCT00216086","phase":"PHASE2","title":"Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer","status":"TERMINATED","sponsor":"Gabi Chiorean, MD","startDate":"2005-05","conditions":"Rectal Cancer","enrollment":22},{"nctId":"NCT02703961","phase":"PHASE3","title":"Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2016-02","conditions":"Cervical Cancer","enrollment":598},{"nctId":"NCT02648841","phase":"PHASE3","title":"A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-07","conditions":"Gastric Cancer","enrollment":588},{"nctId":"NCT02466113","phase":"NA","title":"A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01","conditions":"Colonic Neoplasms, Effects of Chemotherapy","enrollment":430}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":125,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant chemotherapy for experimental group","genericName":"Adjuvant chemotherapy for experimental group","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant chemotherapy uses cytotoxic drugs administered after primary treatment to eliminate residual cancer cells and reduce recurrence risk. Used for Adjuvant treatment in experimental oncology trial (specific cancer type not specified).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}